Collaboration Costs. GSK shall be responsible for Liquidia’s FTE Costs, non-standard costs for lab supplies and manufacturing costs of PRINT Materials and Research Materials incurred solely in connection with the conduct of the Inhaled Plan (and not for activities outside of the conduct of the Inhaled Plan or in furtherance of Liquidia’s collaborations with Third Parties) in accordance with the applicable budget (the “Collaboration Costs”). For clarity, manufacturing costs included in the Collaboration Costs shall not exceed [***] Dollars ($[***]) per single shift day for standard costs and shall not include any costs associated with capital expenditures for Liquidia’s manufacturing facilities unless otherwise agreed by the Parties in accordance with Section 2.1(e)(ii). Notwithstanding anything to the contrary in this Agreement (including the Inhaled Plan and any revisions thereto), GSK shall fund no less than three (3) Liquidia FTEs, but no more than four (4) Liquidia FTEs to work on the Inhaled Collaboration per year. If the activities to be conducted under the Inhaled Plan require additional FTE support, then the JSC shall meet to discuss how to staff such additional activities, which may include contribution of GSK FTEs, at GSK’s cost, to perform activities assigned to Liquidia. GSK shall reimburse Liquidia for the Collaboration Costs as set forth in Section 10.2. For the avoidance of doubt, GSK shall be responsible for all costs and expenses incurred by GSK to conduct the Inhaled Collaboration.
Collaboration Costs. Subject to Section 3.13(a)(vi), the Xxxxx Xxxxxx Entities and the GE Entities shall pay the fees, costs and expenses owed by such parties under any applicable Collaboration Agreements (such fees, costs and expenses, “Collaboration Costs”), in each case in accordance with and subject to the terms of such Collaboration Agreements.
Collaboration Costs. Except as otherwise expressly provided herein or otherwise agreed by the Parties, each Party shall bear all of its own costs and costs of any Third Party acting on its behalf in carrying out those activities assigned to it under the Collaboration.
Collaboration Costs. 2.3.1. Novartis and Akcea will [***] the costs associated with the [***] and [***] under the Pre-Option Development Plan, which [***] Akcea estimates will cost US$[***] for [***]. Novartis will pay Akcea US$[***] for such [***] and [***] as follows:
Collaboration Costs. (a) Orchard shall be liable for the Collaboration Costs for the activities as set out in the Collaboration Plan.
Collaboration Costs. Each Party will be responsible for its own costs associated with performance of this Agreement, except as expressly set forth herein. It is anticipated that the financial benefits of the collaboration will be realized by each Party through sales of the Magnus Analyzer and increased demand for and sales of the NMR Subsystem and LipoScience Diagnostic Applications.
Collaboration Costs. The estimated costs for Translate Bio’s Collaboration Activities will be as set forth in the applicable Collaboration Budget; provided, however, that Sanofi shall be responsible for paying FTE Costs, Out-of-Pocket Costs and Manufacturing Costs up to [**] percent ([**]%) of such costs set forth in the applicable Collaboration Budget with respect to the Translate Bio Collaboration Activities. Any variation in excess of [**] percent ([**]%) of the Collaboration Budget will require Sanofi’s express prior written consent.
Collaboration Costs. Costs incurred by Ionis or Akcea associated with inotersen or IONIS-TTR-LRx under this Agreement will be handled in accordance with Schedule 6.4.1.
Collaboration Costs. 7. Novartis shall be responsible for one hundred percent (100%) of its own costs incurred in performing the activities assigned to it under the applicable Collaboration Plan and, subject to this Section 4.4, one hundred percent (100%) of the Internal Costs (comprised of up to [*], plus, to the extent approved in advance by Novartis, any [*]) and Out-of-Pocket Costs incurred by Sangamo in performing the activities assigned to it under the applicable Collaboration Plan (comprised of the total Out-of-Pocket Costs set forth on Exhibit K ([*]), as [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Confidential Execution Version such Out-of-Pocket Costs may be reallocated in accordance with Section 4.4(e); provided, that the total Out-of-Pocket Costs set forth on Exhibit K shall automatically be deemed to be updated to account for any amended Collaboration Budget approved by the JSC in accordance with Section 4.2 and confirmed in writing by the Parties) (such Internal Costs and Out-of-Pocket Costs, the “Collaboration Costs”); provided, that, prior to Sangamo having any obligation to incur Internal Costs or Out-of-Pocket Costs in excess of the Collaboration Costs as a result of (i) Novartis electing to extend the Collaboration Term pursuant to Section 4.1 or (ii) Novartis selecting a Replacement Target in accordance with Section 4.8, the Parties shall agree upon revised Collaboration Costs (including a revised number of FTEs over a revised period of time for Internal Costs) with respect to Sangamo’s performance of the activities assigned to it under the Collaboration Plan with respect to the extended Collaboration Term or the Replacement Target, as applicable.
Collaboration Costs. [*] [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Confidential Execution Version Schedule 13.2(l) Exceptions to Additional Representations and Warranties by Sangamo [*]
